188 related articles for article (PubMed ID: 29408988)
1. Matrix Metalloproteinase Activity Correlates With Uterine Myoma Volume Reduction After Ulipristal Acetate Treatment.
Courtoy GE; Henriet P; Marbaix E; de Codt M; Luyckx M; Donnez J; Dolmans MM
J Clin Endocrinol Metab; 2018 Apr; 103(4):1566-1573. PubMed ID: 29408988
[TBL] [Abstract][Full Text] [Related]
2. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment.
Courtoy GE; Donnez J; Marbaix E; Dolmans MM
Fertil Steril; 2015 Aug; 104(2):426-34.e1. PubMed ID: 26003270
[TBL] [Abstract][Full Text] [Related]
3. Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation.
Courtoy GE; Donnez J; Marbaix E; Barreira M; Luyckx M; Dolmans MM
Gynecol Obstet Invest; 2018; 83(5):443-454. PubMed ID: 29227976
[TBL] [Abstract][Full Text] [Related]
4. Gene expression changes in uterine myomas in response to ulipristal acetate treatment.
Courtoy GE; Donnez J; Ambroise J; Arriagada P; Luyckx M; Marbaix E; Dolmans MM
Reprod Biomed Online; 2018 Aug; 37(2):224-233. PubMed ID: 29807764
[TBL] [Abstract][Full Text] [Related]
5. Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids.
Szydłowska I; Marciniak A; Nawrocka-Rutkowska J; Rył A; Starczewski A
Int J Environ Res Public Health; 2020 Jan; 17(3):. PubMed ID: 32012826
[No Abstract] [Full Text] [Related]
6. Does Ulipristal Acetate Affect Surgical Experience at Laparoscopic Myomectomy?
Luketic L; Shirreff L; Kives S; Liu G; El Sugy R; Leyland N; Solnik MJ; Murji A
J Minim Invasive Gynecol; 2017; 24(5):797-802. PubMed ID: 28351762
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal Acetate and Extracellular Matrix Production in Human Leiomyomas In Vivo: A Laboratory Analysis of a Randomized Placebo Controlled Trial.
Cox J; Malik M; Britten J; Lewis T; Catherino WH
Reprod Sci; 2018 Feb; 25(2):198-206. PubMed ID: 28929861
[TBL] [Abstract][Full Text] [Related]
8. Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study.
Bizzarri N; Ghirardi V; Remorgida V; Venturini PL; Ferrero S
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():22-6. PubMed ID: 26142912
[TBL] [Abstract][Full Text] [Related]
9. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study.
Ferrero S; Alessandri F; Vellone VG; Venturini PL; Leone Roberti Maggiore U
Eur J Obstet Gynecol Reprod Biol; 2016 Oct; 205():43-7. PubMed ID: 27566221
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of ulipristal acetate (UPA) for the treatment of expulsion uterine myomas: report of two cases.
Palaia I; Del Negro V; Fracassi A; Schiavi M; Di Donato V; Fischetti M; Muzii L; Benedetti Panici P
Gynecol Endocrinol; 2020 Jul; 36(7):660-661. PubMed ID: 31878806
[TBL] [Abstract][Full Text] [Related]
11. [The molecular mechanisms and morphological manifestations of leiomyoma reduction induced by selective progesterone receptor modulators].
Demura TA; Revazova ZV; Kogan EA; Adamyan LV
Arkh Patol; 2017; 79(3):19-26. PubMed ID: 28631712
[TBL] [Abstract][Full Text] [Related]
12. Myoma migration: an unexpected "effect" with Ulipristal acetate treatment.
Willame A; Marci R; Petignat P; Dubuisson J
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(8):1439-44. PubMed ID: 27160112
[TBL] [Abstract][Full Text] [Related]
13. The place of selective progesterone receptor modulators in myoma therapy.
Donnez J; Donnez O; Courtoy GE; Dolmans MM
Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
[TBL] [Abstract][Full Text] [Related]
14. Preoperative Treatment with Ulipristal Acetate before Outpatient Hysteroscopic Myomectomy.
Ferrero S; Scala C; Vellone VG; Paudice M; Vitale SG; Cianci A; Barra F
Gynecol Obstet Invest; 2020; 85(2):178-183. PubMed ID: 31940645
[TBL] [Abstract][Full Text] [Related]
15. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells.
Xu Q; Ohara N; Liu J; Amano M; Sitruk-Ware R; Yoshida S; Maruo T
Mol Hum Reprod; 2008 Mar; 14(3):181-91. PubMed ID: 18216291
[TBL] [Abstract][Full Text] [Related]
16. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
17. Autophagy up-regulation by ulipristal acetate as a novel target mechanism in the treatment of uterine leiomyoma: an in vitro study.
Del Bello B; Marcolongo P; Ciarmela P; Sorbi F; Petraglia F; Luisi S; Maellaro E
Fertil Steril; 2019 Dec; 112(6):1150-1159. PubMed ID: 31843092
[TBL] [Abstract][Full Text] [Related]
18. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells.
Halder SK; Osteen KG; Al-Hendy A
Hum Reprod; 2013 Sep; 28(9):2407-16. PubMed ID: 23814095
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix.
Shin SJ; Kim J; Lee S; Baek J; Lee JE; Cho C; Ha E
Int J Mol Med; 2018 Oct; 42(4):1857-1864. PubMed ID: 30015921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
